Volume 26, Number 8—August 2020
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
|Condition||ICD-9 codes||ICD-10 codes
|Lymphatic and hematopoietic tissue malignancy
|Other immune conditions‡|
|Disorders of immune mechanism||279||D89|
|Functional disorders of neutrophils||288.1||D71|
|Genetic anomalies of leukocytes||288.2||D72.0|
|Decreased leukocyte count||288.5||D72.81|
|Leukocyte disease NEC||288.8||D72.89|
|Leukocyte disease NOS||288.9||D72.9|
|Blood diseases NEC||289.89||D47.4; D75.89; D75.9; D89.2|
|Blood diseases NOS||289.9||D75.9; D75.89|
|Immunologic findings NEC||795.7||R76; R83.4-R87.4; R89.4|
|Nonspecific immune findings NEC and NOS
||R76; R83.4-R87.4; R89.4
|Organ/system malignant tumors||140–199||C00-C07; C11-C19; C22-C80; Z85|
|Neuroendocrine tumors||209||C7A; C7B; D3A|
|Neoplasms of uncertain behavior
|Complications of transplanted organ||996.8||T86|
|Organ transplant status
|Familial Mediterranean fever||277.31||E85.0; M04|
|Amyloidosis NEC||277.39||E85.1; E85.3; E85.8|
|Other CNS demyelination||341||G36; G37.1; G37.3; G37.8; G37.9|
|Acute infective polyneuritis||357||G61.0; G61.9|
|Polyarteritis nodosa and other||446||M30|
|Allergic alveolitis/pneumonitis NOS||495.9||T78.40; J67.9|
|Other alveolar pneumonopathy||516||J84.01; J84.02; J84.09|
|Enteritis and colitis||555–558||K50-K52|
|Lupus erythematosus||695.4||L93.0; L93.2; M32|
|Diffuse connective tissue disease||710||L94; M35.8; M35.9|
|Arthropathy with infection||711||M12.9; M01.X0; M02.10|
|Rheumatoid arthritis/inflammatory polyarthropathy||714||M05-M14|
|Polymyalgia rheumatica||725||M31.5; M35.3
*CNS, central nervous system; ICD9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification; NOS, not otherwise specified; NEC, necrotizing enterocolitis.
†Excludes asymptomatic HIV codes of ICD-9 (V08) and ICD-10 (Z21).
‡Sickle cell disease, asplenia, and psoriatic arthritis were not included in the Greenberg algorithm (20) but are considered to have immune deficiencies by Infectious Diseases Society of America guidelines (5). Adding these to the algorithm only increased the prevalence of immunosuppressive conditions by 0.1%.
§Bone marrow and peripheral stem cell transplant were considered under organ transplant and only considered immunosuppressed if enrollees were currently being given chemotherapeutic agents or immune modulators. Considering these enrollees under other immune conditions in which immunosuppressed does not require receipt of chemotherapeutic agents or immune modulators would increase the overall prevalence of immunosuppressed by 0.01%.
¶Psoriatic arthritis was not included in the Greenberg algorithm and could be an indication for immunosuppressive treatment. Adding this condition did not increase the prevalence of immunosuppressive conditions.